Divergent aftermarket results for Phathom, Cabaletta IPOs

With evidence still suggesting that confidence in biotech IPOs has begun to waver in recent weeks, two new listings traded in opposite directions Friday after pricing offerings ahead of the session. Phathom posted a double-digit gain after upsizing its offering, while Cabaletta

Read the full 420 word article

User Sign In